| INTRODUCTION
Mesalazine (mesalamine) is a first-line treatment for many patients with ulcerative colitis. It is thought to have a beneficial antiinflammatory action via increased expression of peroxisome proliferator-activated receptors in gastrointestinal epithelial cells. [1] [2] [3] [4] [5] Furthermore, it acts to inhibit COX enzymes, thus affecting prostaglandins and decreasing inflammation of the colon. 6 Therapy is expected to improve symptoms within 2-4 weeks of initiation. 7, 8 Currently, mesalazine is the most frequently prescribed drug in the treatment of ulcerative colitis, treating more than 88% of all patients. 9 Furthermore, it is also frequently used as a first line therapy for Crohn's disease despite an absence of robust evidence compared to its utilisation for ulcerative colitis. 10 Sulphasalazine was first introduced in 1942 and greatly improved the success rate of ulcerative colitis management. It is composed of 5-aminosalicylic acid, the active component, and a sulphapyridine moiety, the carrier molecule. 11 Administration of unbound or uncoated 5-aminosalicylic acid revealed that it was readily absorbed in the upper jejunum and unable to reach the colon in therapeutic concentrations. [12] [13] [14] Ingested sulphasalazine largely resists premature absorption and thus is able to serve as a delivery system that transports 5-aminosalicylic acid to the affected regions of the lower intestinal tract. 12 However, Nielsen et al found that up to 30% of patients on sulphasalazine would have adverse events, and these were commonly due to the sulphapyridine moiety. Recent literature has indicated that 15% of patients on 5-aminosalicylic acid experienced at least one adverse event compared to 29% of sulphasalazine patients. 11 Furthermore, sulphasalazine leads to a greater percentage of withdrawal from therapy (13%) compared to patients on 5-aminosalicylic acid (5%).
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Mesalazine preparations were first formulated to avoid adverse effects of sulphasalazine while still maintaining efficacy. 15 Some examples are Asacol (Proctor & Gamble, Cinncinati, OH), containing pellets of 5-ASA which dissolve at pH greater than 7 16 and Pentasa (Shire Pharmaceticals Inc, Wayne, PA), a microsphere formulation consisting of 5-ASA microgranules designed for release in duodenum. 17 Lialda (Shire Pharmaceuticals Inc) uses MMX multimatrix technology to delay and extend delivery of active drug throughout colon. 18, 19 These newer 5-aminosalicylic acid preparations, though constructed to avoid the consequences of sulphasalazine administration, are not without adverse events, most commonly those of arthralgia, myalgia, flatulence, abdominal pain, nausea, diarrhoea and headache. 20 Rectal topical administration of mesalazine can also be used, which may be just as efficacious in maintaining remission as oral formulations, and may have more of a localised/direct effect on inflammation. 21 Many international guidelines recommend the use of mesalazine orally or in combination with topical formulations to treat mild to moderate ulcerative colitis. 22 Although mesalazine does have an improved safety profile compared to sulphasalazine, it is not without side effects. The purpose of this systematic review is to evaluate the adverse effects of mesalazine therapy and whether there is any evidence that these occur in a dose-dependent manner in the setting of treatment for ulcerative colitis. This review further seeks to advise practicing gastroenterologists on how best to prevent and manage these adverse events.
| METHODS

| Search and study selection
An electronic search was performed without language restrictions using the PubMed database from inception up to 1 December 2017.
Relevant studies were identified using various designations for mesalazine: "mesalamine", "mesalamine", "mesalazine", "pentasa", "aminosalicylic acid", "aminosalicylate", "5-aminosalicylic acid", "5-aminosalicylate", "5-ASA", "5ASA", "sulphasalazine", "asacol", "balsalazide", "olsalazine", "5 amino 2 hydroxybenzoic acid", "apriso", "asacol", "canasa", "claversal", "lialda", "mesacol", "mesasal", "mezavant", "mezavant", "rowasa", or "salofalk". Furthermore, free search terms included "safety" or "adverse events" or "drug-related side effects and adverse events". Studies were selected for analysis if they were randomised controlled trials with a minimum treatment time of 6 weeks. Studies of oral 5-aminosalicylic acid therapy for treatment of patients with active ulcerative colitis compared with placebo, sulphasalazine or other 5-aminosalicylic acid formulations were considered for inclusion.
Studies that compared once daily 5-aminosalicylic acid treatment with dose ranging studies of 5-aminosalicylic acid were also considered for inclusion. Data obtained from randomised controlled trials was used to estimate incidence rates of each adverse event. These rates were formulated based on incidence of adverse events per patient treated with mesalazine. Case reports were only used to identify adverse events of mesalazine not previously identified by randomised controlled trials but were not used to determine incidence rates.
Several landmark trials have examined mesalazine at 2.4 vs 4.8 g daily with regard to clinical efficacy and safety. In examining a dose dependent relationship between high vs low dosing, we have defined high-dose mesalazine as >2.4 g/day and low-dose mesalazine as ≤2.4 g/day consistent with the studies focused on mesalazine dosing.
Two reviewers (P.S. and N.N.) independently screened all titles and abstracts identified by the search strategy. Full text of articles deemed to be potentially relevant was independently assessed by the aforementioned two reviewers, who made the final decision for inclusion.
| Data extraction and risk of bias assessment
Two reviewers (P.S. and A.A.) independently assessed methodological risk of bias and performed data extraction. Safety data (adverse effects and/or complications) when available was collected. Discrepancies in bias scoring and data extraction were discussed during a consensus meeting. The quality of randomised studies was evaluated using domain-based risk of bias tables as recommended by the Cochrane Collaboration. 23 This approach requires studies to be assessed across six domains that are subject to potential bias, including sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. The overall risk of bias for a study is considered low if the risk of bias is low in all domains, high if the risk of bias is high in at least one domain, moderate if the risk of bias is moderate in at least one domain (with no domains having a high risk of bias), or unclear if the risk of bias is unclear in at least one domain (with no domains having a high or moderate risk of bias). The quality of nonrandomised studies was assessed using the Newcastle-Ottawa scale, a tool which allows for quality appraisal of nonrandomised studies in meta-analyses. 24 The highest score is 9. We then used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to determine the overall quality of evidence.
GRADE uses several domains, including design, consistency, precision, directness and publication bias, to rate the quality of evidence as high, moderate, low or very low. These ratings represent an assessment of the likelihood that further research would lead to changes in the estimate of effect. 25 Detailed results from the quality assessment are provided in the Supporting information.
3 | RESULTS
| Search results
A literature search for relevant studies from inception to 1 December 2017 of the MEDLINE database was conducted, a total of 3581 articles were considered initially for review. Of these, 3573 articles were screened, 622 full texts were reviewed, and 91 were included. mesalazine dosing. The ASCEND I trial was a randomised, doubleblind, placebo controlled trial which compared 2.4 g vs 4.8 g daily of delayed release mesalazine for 8 weeks to treat mild-to-moderate ulcerative colitis. Both treatment groups had similar incidence rates of adverse events (32% vs 39%). 26 ASCEND II trial was modified to include only those patients with moderate ulcerative colitis based on the subgroup analysis of ASCEND I, and findings were consistent such that a similar incidence rate of adverse events occurred in the two groups (35% vs 44%). 27 In the ASCEND III trial, which compared 2.4 g/day vs 4.8 g/day over a period of 6 weeks, the most commonly identified adverse events included ulcerative colitis exacerbation, nausea and headache, which were similar in frequency between the two treatment groups (Table 1) . 28 In a separate randomised controlled trial comparing mesalazine 2.4 g/day vs 4.8 g/day over an 8 week period, there were no notable differences between treatment groups with respect to frequency of treatment-related adverse events for any safety parameter. 18 Another randomised controlled trial comparing oral mesalazine 2.25 g vs 4 g daily over 8 weeks, found that the incidence of adverse events was 92.5% vs 76.6% in the two groups, with no statistically significant difference between the two dose groups. 29 Several studies have also compared daily vs twice daily mesalazine dosing with regard to both efficacy and safety. In a randomised controlled trial with 280 patients with mild to moderately active ulcerative colitis who received either mesalazine 2.4 g twice daily vs 4.8 g once daily for 8 weeks, no clinically significant difference in safety was observed between the two dosing regimens. 19 Another randomised controlled trial compared mesalazine 1.6-2.4 g once daily to b.d. dosing, and found similar efficacy between the two groups with no significant difference in severe adverse events (3.5% in the once daily group and 1.8% in the twice daily group). 30 In a double-blind, double dummy, randomised, multicentre non-inferiority study in which 301 patients with quiescent ulcerative colitis were randomly assigned to treatment groups and administered prolonged-release oral mesalazine at doses of 1.5-2.25 g/day once daily or divided into three doses daily for 52 weeks, there was no statistically significant difference in the incidence of adverse events in each group (72.4% in daily group vs 76.5%
in three times daily group). 31 A similar study with once daily and three times daily dosing of mesalazine also showed no difference in incidence of adverse events. 32 Several other studies have similarly demonstrated no difference in adverse events between once daily compared to divided dosing for mesalazine. [33] [34] [35] [36] [37] [38] [39] [40] [41] Several different formulations of mesalazine have been compared with regards to efficacy as well as safety profile. In a 1-year, randomised, multicentre study comparing Lialda to Asacol, it was found that there was no difference between the treatment groups with respect to frequency of treatment-emergent adverse events, and no evidence of a dose relationship for Lialda or Asacol for any safety parameter. 42 In a similar randomised controlled trial, no difference was found with regard to safety outcomes when Lialda was compared to pH dependent release mesalazine. 
| Gastrointestinal adverse events
Inflammatory/UC exacerbation
The incidence of inflammatory adverse events/ulcerative colitis exacerbation has been reported to occur in 0.5%-6.5% of patients who were treated with mesalazine (Table 2 ). This adverse event may be due to lack of response to drug therapy, worsening of disease intrinsically or worsening of symptoms by the 5-aminosalicylic acid agent-the precise mechanism of the latter is not completely elucidated. Scheurlen et al postulated that mechanism of diarrhoea caused by mesalazine was attributed to a secretory mechanism secondary to inhibition of ileal and colonic Na + /K + ATPase. 59 Another proposed mechanism was an alteration of arachidonic acid metabolism which manifested mainly with secretory diarrhoea and malabsorption. 60 In a randomised controlled trial comparing placebo vs mesalazine granules 1.5 g daily, it was found that the most common adverse All differences between low-dose and high-dose regimens were found to be insignificant.
event leading to withdrawal of therapy was ulcerative colitis exacerbation, which occurred in 6.2% patients. 47 In a randomised controlled trial comparing balsalazide 6.75 g vs balsalazine 2.25 g vs mesalazine 2.4 g, two of the 51 patients taking mesalazine had worsening of colitis symptoms leading to withdrawal of agent. 46 If a patient has exacerbation of symptoms after starting mesalazine, it is reasonable to consider withdrawal of the agent as the patient may have intolerance to therapy.
Furthermore, caution should be exercised when prescribing mesalazine to patients who have a history of hypersensitivity reaction to aspirin, as the similarities in their chemical structure and function (both serve to inhibit cyclooxygenase enzymes) can lead to cross-reactivity between the two compounds, further contributing to hypersensitivity. Such patients may need to undergo mesalazine desensitisation protocols. 6 
Generalised gastrointestinal complaints
Common gastrointestinal complaints that patients may develop on mesalazine therapy include abdominal pain not otherwise specified (0.2%-5.9%), abdominal pain (upper) (0.4%-2.3%), diarrhoea (0.5%-10.8%), constipation (5.9%), dyspepsia (0.7%-2.2%), heartburn/reflex (2.3%-5.4%), nausea (0.2%-23.3%) and vomiting (1%-3%).
In a randomised controlled trial comparing prevention of relapses with olsalazine and mesalazine, there was no difference between relapse prevention between the two formulations. Of the 50 patients on mesalazine, two patients developed severe abdominal pain, requiring cessation of therapy. Two patients developed nausea and rash, and were still able to continue with treatment. 51 In a randomised controlled trial comparing 2 g daily of mesalazine to 1 g daily, the overall incidence of adverse events between the two groups was not found to be significant (42.9% vs 36.4%, P = 0.24). In this study, the incidence of abdominal pain was found to be 3.4% and 2.7% in high and low-dose groups, and the incidence of diarrhoea was 2.9% and 2.1%, respectively. 52 Patients were not withdrawn from therapy due to symptomatic complaints. In a randomised controlled trial comparing mesalazine 2.4 g once daily or divided dosing twice daily, it was found that the incidence of abdominal pain not otherwise specified was 1.3%
and 0.9%, respectively. These two groups had an incidence of ulcerative colitis exacerbation to be 1.8% and 0.4%. Diarrhoea was reported in 1.3% of patients taking mesalazine once daily and 0.9% who used it twice daily. Upper abdominal pain reported in these groups was 0.4% and 1.3%. 45 In a randomised controlled trial comparing mesalazine 1.6-2.4 g once daily to divided dosing twice daily, it was found that the incidence of flatulence was 0% and 0.4%, abdominal pain not otherwise specified 0% and 0.2%, and incidence of nausea 0% and 0.2%, respectively, and each adverse event required withdrawal of the drug. Consideration could be made for additional medication to help manage symptoms, i.e. nausea, if the benefit of ongoing mesalazine therapy outweighs the risks.
Pancreatitis
Incidence of pancreatitis has been reported to be in the range of 0.3%-1.8% (Table 2 ). In a randomised controlled trial comparing mesalazine 2.4 g vs 4.8 g daily, it was found that in both groups, one patient developed pancreatitis. Mechanism of pancreatitis was | 1601 postulated to be secondary to mesalazine hypersensitivity as both patients had not received mesalazine for at least 6 weeks prior to entering the trial. Both clinical episodes resolved upon discontinuation of the drug and symptomatic treatment. 19 Another randomised controlled trial evaluating mesalazine granules at 1.5 g daily reported an incidence of pancreatitis at 0.3%, leading to withdrawal of drug therapy. 47 In a retrospective study, adults who were new users of MMX mesalazine were identified from a large administrative healthcare claims database, and acute pancreatitis incidence rates were compared between patients on MMX mesalazine vs comparator therapies. The incidence of acute pancreatitis while on MMX mesalazine when adjusted for cofounders was found to be 0.76%. 57 If pancreatitis develops, we would recommend discontinuation of mesalazine until the episode has resolved. Consideration could be given to using a topical formulation or lower dose of mesalazine after the episode of pancreatitis has resolved, however, cases of pancreatitis have also been reported after use of mesalazine suppositories. 61 
| General adverse events
Patients on mesalazine may develop generalised complaints such as asthenia (1%-3%), fatigue (0.2%-7%), depression or mood changes (4.6%), insomnia (3%), dental caries (0.7%-3.3%) or paresthesia/pruritis (0.5%; Table 3 ). If these adverse events occur without other laboratory abnormalities, discontinuation of therapy should be only be undertaken if the symptoms are functionally debilitating to the patient. In a randomised controlled trial comparing mesalazine 1.6-2.4 g once daily to twice daily dosing, it was found that the incidence of fatigue was 0.2% and 0%, respectively, and patients were continued on therapy. 30 For most of the above general adverse events, 44 it is reasonable to symptomatically treat the patient. Consider closely monitoring the patient while persisting on mesalazine therapy with the patient's primary care physician and/or psychiatry.
Incidence of neurological events from mesalazine therapy has been reported for headache (0.5%-13.7%), dizziness (1.2%-5.9%) and urinary retention (0.6%). In one multicentre, randomised, doubleblind trial that was conducted to compare once daily mesalazine 2.4 g/day with twice daily 1.6 g/day, it was found that 0.5% and 1.5% of patients developed headache, respectively, but were not discontinued from therapy. 44 A similar study compared mesalazine 2.4 g/day vs mesalazine 4.8 g/day, and found that 6% and 4.7% developed headache, but again patients did not need to discontinue therapy. 18 In the same study conducted by Kamm et al, it was found that out of the 4.8 g/day group, 1.2% of patients developed dizziness as well. Thus, our recommendation is that if patients develop headache or dizziness while on mesalazine therapy, with no other laboratory or clinical abnormalities, then they should remain on therapy with close observation.
| Cardiac adverse events
Cardiac adverse drug events occur at a frequency of 0%-0.3% while on mesalazine therapy including cardiomyopathy, myocardial infarction, AV block, and ventricular dysfunction (Table 4 ). In a randomised controlled trial comparing mesalazine 1.6-2.4 g once daily to twice daily dosing, it was found that the incidence of cardiomyopathy was 0% and 0.2%, and the incidence of myocardial infarction was 0.2% and 0%, respectively. 30 Patients who developed cardiomyopathy were withdrawn from therapy. 30 Rarely, the mesalazine-induced cardiomyopathy will present as cardiogenic shock. 71 Similar to incidence of cardiomyopathy, incidence rates of myocardial infarction and AV block have also been reported to be low, 0%-0.3% each. 30 Any patient who develops one of these adverse events should be withdrawn from mesalazine and referred for cardiology evaluation.
Several case reports have reported that mesalazine can cause myocarditis or pericarditis such that patients will present with chest pain, shortness of breath and fever within the first 28 days after initiating 5-ASA. Physical exam, EKG, and diagnostic imaging will yield findings consistent with myocarditis, with or without accompanying pericarditis. Prompt discontinuation of the 5-aminosalicylic acid agent will result in resolution of symptoms within days, without need for adjunctive therapies. 59 Corticosteroids could be considered to expedite resolution of pericarditis or myocarditis. 70 Re-challenge with 5-aminosalicylic acid puts patient at high risk for recurrence of inflammation.
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T A B L E 3 Adverse events: general 
| Hepatic adverse events
Incidence of elevated liver enzymes has been reported in the range of 0%-4% (Table 5 ). In a randomised controlled trial comparing 1.5-3.0 g daily of mesalazine, one patient (1%) in the lower dose group developed a rash, and was subsequently found to have elevated ALT and AST. Upon discontinuation of the drug, the patient's liver enzymes normalised. However, when the medication was re-started 4 weeks later, the liver enzymes again increased. 72 In a multicenter randomised controlled trial of 251 patients with active ulcerative colitis, subjects were given treatment with mesalazine modified release tablets (n = 123) or enteric coated tablets (n = 125) at 800 mg three times daily for 8 weeks. Of these two groups, the incidence of adverse events was found to be similar. Both groups had patients with elevation in total and direct bilirubin levels, however, only the modified release formulation resulted in an increase in ALT levels-5 patients (4.07%) developed this complication compared to no patients on enteric coated mesalazine. In all of these cases of laboratory abnormalities, no patient had to be withdrawn from the study. 73 Case reports have indicated that mesalazine may cause a granulomatous hepatitis on biopsy. 74, 75 Drug-induced liver injury is the likely diagnosis if the liver transaminases are significantly elevated, with ALT and AST commonly elevated in the range of 500-1000 U/L. 76 Liver biopsy does not need to be pursued, but will reveal noncaseating granulomas with infiltration of epithelioid cells if obtained due to diagnostic uncertainty.
Before a patient is started on mesalazine therapy, a comprehensive metabolic panel should be considered to establish a baseline.
While on therapy, the panel should be assessed yearly for any acute changes. Consideration could be given to continuation of mesalazine if there is a mild increase in liver enzymes. Other etiologies for elevated liver enzymes such as alcohol consumption or weight gain must be considered as well. In cases of significant transaminitis, mesalazine should be discontinued and systemic steroids should be considered, such as 40 mg/day of prednisone, followed by an adequate taper to treat the mesalazine-induced hepatitis. 74 
| Musculoskeletal adverse events
Musculoskeletal adverse events are reported in up to 7% of patients (Table 6 ). In a randomised controlled trial comparing 2 to 1 g daily of mesalazine, the incidence of back pain was found to be 0.6% and 2.1% respectively. 52 These patients did not require withdrawal from medication. In a randomised controlled trial comparing mesalazine 1.6-2.4 g once daily to twice daily dosing, it was found that the incidence of plantar fasciitis was 0% and 0.2% respectively, leading to withdrawal of medication in the one patient who developed this. 30 The withdrawal of mesalazine therapy for patients who develop musculoskeletal adverse events depends on the discretion of the prescribing physician. For patients who develop musculoskeletal adverse events while on therapy, we would recommend monitoring 
| Pulmonary adverse events
In randomised controlled trials examining mesalazine efficacy, pulmonary adverse drug events have been reported including bronchitis (1.1%-2.7%), nasopharyngitis (3.2%-38.9%), sinusitis (1.1%-7.2%), rhinitis (3%), cough (1%) and upper respiratory tract infections (2.7%-7.9%; Table 7 ). In a randomised controlled trial comparing 2 to 1 g of mesalazine daily, the incidence of pulmonary adverse events was found to be similar between the two groups. Incidence of bronchitis was 1.1% and 2.7%, incidence of nasopharyngitis 5.7% and 3.2%, and incidence of sinusitis 3.4% and 1.1%, respectively. 52 In another study comparing efficacy and safety of three mesalazine formulations, nasopharngitis was reported in all three groups at incidences of 16.7%, 15.6% and 10.8% of patients. 77 The aforementioned adverse events, all documented in randomised controlled trials, do not require withdrawal from therapy. Such clinical presentations can be diagnosed based on the patient's symptoms without radiological evidence, and can be managed symptomatically.
The development of pneumonia as an adverse event to mesalazine therapy has been documented in case reports. These span from interstitial pneumonitis, 78-81 interstitial pneumonia, 82 Wegener's granulomatosis 83 and eosinophilic pneumonia. [84] [85] [86] [87] [88] [89] Development of bronchiolitis obliterans with organising pneumonia has also been reported, with improvement noted once the drug has been discontinued and patient has received corticosteroids. 90, 91 Thus, when patients on mesalazine develop upper respiratory tract symptoms, patients should be evaluated for symptoms which may suggest pneumonia or pneumonitis, including fever or other abnormalities in vital signs. For patients with suspicion for pneumonia or pneumonitis, radiographic evaluation should be performed and if confirmed, the patient should be withdrawn from therapy, and referred for pulmonary evaluation.
| Renal adverse events
Renal adverse drug events have been reported for patients on mesalazine therapy including interstitial nephritis and renal failure (Table 8 ). In a randomised controlled trial comparing 1.5-3.0 g mesalazine, one patient (1%) in the former group had a moderate rise in creatinine level (but still remained within normal limits). This patient was continued on the mesalazine 1.5 g daily regimen. Approximately 3 months later, there was a significant rise in creatinine and renal biopsy diagnosed interstitial nephritis. Renal function recovered after discontinuing the medication and starting a course of oral corticosteroids. 72 In a randomised controlled trial comparing mesalazine 1.6-2.4 g once daily to twice daily dosing, incidence of renal failure was 0% and 0.2%, leading to withdrawal of the therapy in the latter group. 30 In a randomised controlled trial comparing placebo to Case series 94 1 mesalazine 1.5 g granules, it was found that in the treatment group (n = 388), the mean creatinine clearance remained constant throughout study. A decrease in creatinine clearance was observed in a total of four patients (incidence 1%), however, these patients continued on treatment. In this same study, it was found that one patient (0.3%) developed proteinuria, and had to be discontinued from therapy. 47 To evaluate impact of 5-aminosalicylic acid agents on renal function, forty patients with ulcerative colitis in complete remission for 6 months were randomised to either olsalazine (n = 20) or mesalazine (n = 20) for 9 months. This study found that there was no significant reduction in glomerular filtration rate while on either therapy. 92 As it has been noted that nephrotoxicity with regard to mesalazine therapy has been documented to occur within 12 months of initiation of treatment, 1 we recommend monitoring creatinine level at initiation of therapy, at 6 months, and again at 12 months. 
| Reproductive adverse events
Incidence of erectile dysfunction while on mesalazine therapy has been noted to be 0.5% in one observational study. 1 Furthermore, a retrospective study found that out of eight male patients with inflammatory bowel disease found to be infertile, seven were treated with mesalazine. Six of these seven patients discontinued their mesalazine treatment. Sperm motility and total motile sperm count were significantly improved in all patients after discontinuation, and most were able to conceive successful pregnancy with their partners. 94 Thus, in male patients on mesalazine who experience a decrease in libido, sexual dysfunction, or difficulty conceiving a pregnancy, a trial of mesalazine discontinuation is a reasonable first approach (Table 9) . If no change occurs in sperm function, the drug can likely be resumed. In the inflammatory bowel disease patient population, female infertility secondary to mesalazine treatment has not been reported. Many physicians and patients may erroneously speculate that there is a dose-dependent relationship between mesalazine therapy and development of adverse events, and subsequently may use lower doses in attempt to minimise risk of adverse events. It does not, however, appear that there is a dose-dependent effect of mesalazine in relation to adverse events. 58 High-dose mesalazine treatments appear to be as safe as low dose therapy, and are not associated with an increased incidence of adverse events. 15 This may be due to the fact that most of the aforementioned adverse effects are driven by a hypersensitivity reaction mechanism. Pre- 
